Developing Controllable Tumor Infiltrating Lymphocyte Therapies

Video

Jan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.

“Melanoma is a very attractive target for TIL treatment because there are historic data showing that even un-engineered TIL can be very effective in patients that have failed several lines of treatment initially... for these patients, of which there's several thousands in the US annually, there are no good treatment options available right now. It has been shown that you can extract lymphocytes from the tumors of those patients, treat them, and get quite good response rates in the range of 30 to 50% as well as complete responses. This is the patient population that we will offer in a clinical trial at MD Anderson.”

Obsidian Therapeutics is targeting oncologic indications such as multiple myeloma and non-small cell lung cancer with tumor-infiltrating lymphocyte (TIL) therapies engineered with the use of their cytoDRIVE platform.

Obsidian presented advancements to their cytoDRIVE platform at the 2022 American Society of Gene and Cell Therapy Annual Meeting, May 16-19, 2022, in Washington DC. These advancements should improve efficacy and reduce toxicity of TILs by allowing controllable timing and protein levels of the therapies.

CGTLive spoke with Jan terMeulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, to learn more about the company’s focus on TILs. He discussed the advantages of the cytoDRIVE platform.

REFERENCE
Sethi D, Li DJ, Davoodi S, et al. Armoring T-Cells with Regulatable, Membrane Tethered Cytokines Using Improved Drug-Responsive Domain Technology (cytoDRIVE™). Presented at: ASGCT 25th Annual Meeting, May 16-19, 2022. Abstract #1089
Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.